BPGbio to present novel Huntington's Disease and Alzheimer's Disease research at the Society for Neuroscience 2024 annual meeting.

BPM31510IV is also a lead candidate to treat solid tumours such as glioblastoma multiforme and pancreatic cancer.

Boston, Massachusetts Tuesday, October 1, 2024, 14:00 Hrs [IST] ...

BOSTON–(BUSINESS WIRE)–#bpgbio—BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that the U.S. Food ...

BPGbio Enhances Commercial Capabilities with Industry Veteran Addition. BOSTON, September 16, 2024--(BUSINESS WIRE)--BPGbio, ...

Company is planning a potential pivotal trial of BPM31510IV targeting multiple CoQ10 deficiency mutations at multiple US and EU sites BOSTON, September 30, 2024--(BUSINESS WIRE)--BPGbio ...

BOSTON--(BUSINESS WIRE)--BPGbio, Inc., a pioneering biology-first, AI-powered, clinical-stage biopharma specializing in mitochondrial biology and protein homeostasis, today announced the ...

BPGbio, a pioneering biology-first, AI-powered, clinical-stage biopharma specializing in mitochondrial biology and protein homeostasis, and Joslin Diabetes Center, the world's leading diabetes ...

WALTHAM, MA — A biotech company is leaving Framingham behind for the new Third Avenue life science building in Waltham. BPGbio announced this week that a lease agreement was reached for 70,000 sq.

BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that Vivek K. Vishnudas, Ph.D., Chief ...